EW Edwards Lifesciences
Health Care · Health Care Equipment · close $86.60 (2026-10-16) · latest quarter in EDGAR: 2026-06-30
Edwards Lifesciences (EW) has a ThetaGrade House Rating of 52/100 (grade C), ranking #21 of 150 in Health Care. Its strongest pillars are balance sheet (86) and cash flow (65); its weakest is valuation (29). TTM revenue growth is 14.6% and operating margin 22.3%.
Data as of .
Analyst sentiment
weight 7.5% · 50| Consensus score (1–5) (3.8%) | derived | 77 |
| 90-day net rating shift (3.8%) | derived | 49 |
Growth
weight 30.83% · 37| Revenue growth YoY (TTM) (12.3%) | 14.6% | 64 |
| EPS growth YoY (TTM) (12.3%) | -75.0% | 13 |
| Revenue acceleration (6.2%) | -3.1% | 30 |
Profitability
weight 18.5% · 54| Operating margin (9.9%) | 22.3% | 77 |
| 4Q gross-margin change (8.6%) | -1.0% | 27 |
Balance sheet
weight 18.5% · 86| Net debt / EBITDA (9.9%) | -1.44× | 89 |
| Current ratio (4.9%) | 4.52 | 74 |
| Interest coverage (3.7%) | 71.03× | 93 |
Cash flow
weight 12.33% · 65| FCF margin (6.2%) | 22.0% | 79 |
| FCF yield (6.2%) | 2.7% | 50 |
Valuation
weight 12.33% · 29| P/E (inverted) (6.2%) | 49.77× | 21 |
| EV/Sales (inverted) (6.2%) | 7.31× | 37 |
Technicals (EOD)
| RSI(14) | 49.2 |
| EMA 9 / 21 | 86.41 / 86.63 |
| 200-day SMA | 85.14 |
| Volume vs 20d avg | 1.06× |
| 20-day return | -1.9% |
Exit-rule monitor
- EXITRating break: House Rating below 60
Data source per metric (SEC XBRL tag or derivation): Revenue: RevenueFromContractWithCustomerExcludingAssessedTax · Gross profit: GrossProfit · Operating income: OperatingIncomeLoss · Interest expense: InterestExpenseNonoperating · D&A: DepreciationDepletionAndAmortization · EPS: EarningsPerShareDiluted · Market cap: SEC shares (dei EntityCommonStockSharesOutstanding (cover page)) × EOD close · P/E: EOD close ÷ SEC TTM EPS (EarningsPerShareDiluted).
Get rating changes like EW's in the free Daily Brief
The market’s key events and signals, digested before the open.
- ✓ Pre-market Daily Brief: events, headlines, rating changes (2-min read)
- ✓ Sunday: Top 5 Weekly Picks, exit alerts, CSP put watchlist
- ✓ OPEX, FOMC, CPI and jobs-day reminders
Free. Want more? See Premium (waitlist).
FAQ
- What is EW's House Rating?
- EW scores 52 out of 100 (grade C) as of 2026-10-16, ranking #21 of 150 Health Care stocks we cover.
- What do analysts say about EW?
- ThetaGrade's analyst-sentiment pillar for EW scores 50/100 against its sector peers, which we read as mixed. This is our own derived score; we do not republish individual analyst ratings, counts or targets.
- When does EW report earnings next?
- EW's next earnings report is estimated for about 2026-10-29 (window 2026-10-22 to 2026-11-05), based on its past SEC 8-K earnings filings. This is an estimate, not a company-confirmed date.
- Is EW a buy?
- ThetaGrade does not give personal advice. The House Rating is an educational, rules-based summary of public data; see the methodology for how it is built.
Sources: SEC EDGAR filings (fetched 2026-10-18), Finnhub recommendation trends, Massive EOD prices. Scores are sector percentiles; a factor without usable data is a data gap: it is left out and the remaining weights are renormalized (nothing is imputed). Educational only. Methodology